開設賬戶
模擬帳戶
關於我們
即時報價及新聞
市場分析
財經日曆
每日市場分析
交易平台
下載及介紹
使用教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
繁
简
EN
客户登入
開設賬戶
模擬帳戶
繁
简
EN
客户登入
開設賬戶
模擬帳戶
關於我們
上志國際介紹
上志國際特點
即時報價及新聞
即時報價
即時新聞
市場分析
財經日曆
市場分析
交易平台
平台特點
平台教學
交易細則
各項細則
資金提存
推廣和資訊
常見問題
聯絡我們
關於我們
交易細則
貴金屬市場
交易平台
市場分析
推廣和資訊
常見問題
聯絡我們
繁
简
EN
以色列常駐聯合國代表:伊斯蘭國、真主黨和伊朗伊斯蘭革命衛隊繼續從敘利亞境內對以色列構成威脅。
2026-09-17
以色列常駐聯合國代表:伊斯蘭國、真主黨和伊朗伊斯蘭革命衛隊繼續從敘利亞境內對以色列構成威脅。
返回
其他消息
2026-09-17
UK gilt yields slipped ahead of the Bank of England's rate decision as investors largely expect no change and will focus on the vote split and the BoE's assessment of second‑round inflation effects. Markets assign a 19% probability to a Thursday hike but fully price three 25bp hikes by March 2027. The US Federal Reserve raised rates on Wednesday as widely expected; a Fed official said inflation remains very high, increasing the prospect of further tightening. Tradeweb data showed the 10‑year UK
UK gilt yields slipped ahead of the Bank of England's rate decision as investors largely expect no change and will focus on the vote split and the BoE's assessment of second‑round inflation effects. Markets assign a 19% probability to a Thursday hike but fully price three 25bp hikes by March 2027. The US Federal Reserve raised rates on Wednesday as widely expected; a Fed official said inflation remains very high, increasing the prospect of further tightening. Tradeweb data showed the 10‑year UK gilt yield down 1.3 bps at 5.282%.
2026-09-17
AstraZeneca will invest about 200 mln yuan to upgrade its Wuxi production and supply base with a new drug development and supply building to support process development and production for its cardiovascular drug candidates and to back global supply after commercialisation. The 5,800 sq m facility is scheduled to enter service in Q4 2029 and is expected to have annual capacity of about 400 mln tablets. Upon completion, the Wuxi site will engage in commercial-stage process development and could be
AstraZeneca will invest about 200 mln yuan to upgrade its Wuxi production and supply base with a new drug development and supply building to support process development and production for its cardiovascular drug candidates and to back global supply after commercialisation. The 5,800 sq m facility is scheduled to enter service in Q4 2029 and is expected to have annual capacity of about 400 mln tablets. Upon completion, the Wuxi site will engage in commercial-stage process development and could become AstraZeneca’s first APAC base capable of supporting a new drug’s global launch and supply.
Chat with us
, powered by
LiveChat